PURPOSE: To our knowledge, this is the first study exploring the association of childhood non-Hodgkin's lymphoma (NHL) with serum adiponectin and leptin levels in a nationwide case-control series. In addition, expression of adiponectin receptors in NHL specimens was assessed, and the association between adipokines and childhood NHL survival and prognosis was examined. PATIENTS AND METHODS: We studied 121 incident childhood (0 to 14 years) NHL cases registered in the Nationwide Registry for Childhood Hematological Malignancies (1996 to 2006) and an equal number of matched controls, for whom sociodemographic, lifestyle, prenatal characteristics, and fasting blood serums were collected. Serum adiponectin and leptin levels were determined. Immunohistochemisty for adiponectin receptors expression was performed on commercially available adult NHL specimens (n = 30) and in a subset of childhood NHL cases (n = 6) that were available. Summary statistics, multiple conditional logistic regression analyses, and survival analysis were performed. RESULTS: Higher serum adiponectin, but not leptin, levels were independently associated with childhood NHL (odds ratio, 1.82; 95% CI, 1.30 to 2.56), after adjusting for obesity and established risk factors. Higher adiponectin levels at diagnosis were positively associated with relapse and poor survival, but hormone levels did not differ among NHL subtypes. Adiponectin receptors 1 and 2 were present in 90% and 57% of adult samples and in 83% and 100% of childhood NHL samples, respectively. CONCLUSION: Elevated serum adiponectin, but not leptin, levels are independently associated with childhood NHL and poor prognosis. Adiponectin receptors are expressed in NHL, suggesting that adiponectin may represent not only a potential clinically significant diagnostic and prognostic marker but also a molecule that may be implicated in NHL pathogenesis.
PURPOSE: To our knowledge, this is the first study exploring the association of childhood non-Hodgkin's lymphoma (NHL) with serum adiponectin and leptin levels in a nationwide case-control series. In addition, expression of adiponectin receptors in NHL specimens was assessed, and the association between adipokines and childhood NHL survival and prognosis was examined. PATIENTS AND METHODS: We studied 121 incident childhood (0 to 14 years) NHL cases registered in the Nationwide Registry for Childhood Hematological Malignancies (1996 to 2006) and an equal number of matched controls, for whom sociodemographic, lifestyle, prenatal characteristics, and fasting blood serums were collected. Serum adiponectin and leptin levels were determined. Immunohistochemisty for adiponectin receptors expression was performed on commercially available adult NHL specimens (n = 30) and in a subset of childhood NHL cases (n = 6) that were available. Summary statistics, multiple conditional logistic regression analyses, and survival analysis were performed. RESULTS: Higher serum adiponectin, but not leptin, levels were independently associated with childhood NHL (odds ratio, 1.82; 95% CI, 1.30 to 2.56), after adjusting for obesity and established risk factors. Higher adiponectin levels at diagnosis were positively associated with relapse and poor survival, but hormone levels did not differ among NHL subtypes. Adiponectin receptors 1 and 2 were present in 90% and 57% of adult samples and in 83% and 100% of childhood NHL samples, respectively. CONCLUSION: Elevated serum adiponectin, but not leptin, levels are independently associated with childhood NHL and poor prognosis. Adiponectin receptors are expressed in NHL, suggesting that adiponectin may represent not only a potential clinically significant diagnostic and prognostic marker but also a molecule that may be implicated in NHL pathogenesis.
Authors: E T Petridou; A Pourtsidis; N Dessypris; K Katsiardanis; M Baka; M Moschovi; S Polychronopoulou; D Koliouskas; V Sidi; F Athanasiadou-Piperopoulou; M Kalmanti; M Belechri; C La Vecchia; M P Curado; I Skalkidis Journal: Arch Dis Child Date: 2008-08-01 Impact factor: 3.791
Authors: Eleni Th Petridou; Stavroula K Dikalioti; Alkistis Skalkidou; Elisabeth Andrie; Nick Dessypris; Dimitrios Trichopoulos Journal: Cancer Causes Control Date: 2007-07-26 Impact factor: 2.506
Authors: Anne Kricker; Bruce K Armstrong; Ann Maree Hughes; Chris Goumas; Karin Ekström Smedby; Tongzhang Zheng; John J Spinelli; Sylvia De Sanjosé; Patricia Hartge; Mads Melbye; Eleanor V Willett; Nikolaus Becker; Brian C H Chiu; James R Cerhan; Marc Maynadié; Anthony Staines; Pierluigi Cocco; Paolo Boffeta Journal: Int J Cancer Date: 2008-01-01 Impact factor: 7.396
Authors: C S Mantzoros; M Trakatelli; H Gogas; N Dessypris; A Stratigos; G P Chrousos; E Th Petridou Journal: Eur J Cancer Date: 2007-05-23 Impact factor: 9.162
Authors: Catherine J Williams; Nicholas Mitsiades; Elias Sozopoulos; Alex Hsi; Alicja Wolk; Artemissia-Phoebe Nifli; Sofia Tseleni-Balafouta; Christos S Mantzoros Journal: Endocr Relat Cancer Date: 2008-03 Impact factor: 5.678
Authors: Emily S Tonorezos; Gloria L Vega; Charles A Sklar; Joanne F Chou; Chaya S Moskowitz; Qianxing Mo; Timothy S Church; Robert Ross; Peter M Janiszewski; Kevin C Oeffinger Journal: Pediatr Blood Cancer Date: 2011-01-19 Impact factor: 3.167
Authors: Shannon M Conroy; Gertraud Maskarinec; Yukiko Morimoto; Adrian A Franke; Robert V Cooney; Lynne R Wilkens; Marc T Goodman; Brenda Y Hernadez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-01-08 Impact factor: 4.254